Julphar's Insulin Project Receives Assistance From Parexel Consulting

BMI Core View: Drugmakers based in emerging markets will increasingly produce hard-to-manufacture pharmaceuticals. Firms in developing countries enjoy low operating costs but have traditionally lacked the expertise and equipment to make advanced therapeutics such as biologics. As economies in these non-traditional markets grow, capital will be released for establishing modern production facilities, with output destined for domestic consumption and

To read the full article, please choose one of the following options: